Canaan backs Pathios' search for small molecule drugs that hit 'orphan' GCPR
As fruitful as G protein-coupled receptors have proved for modern medicine — by common estimates, more than 30% of FDA-approved drugs target this class of proteins — there are still dozens of “orphan” GPCRs whose endogenous ligands are poorly understood. One of them is GPR65, a pH sensing receptor that British biotech Pathios believes plays a crucial role in both cancer and autoimmune diseases.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters